By the end of 2024, EMA released updated IDMP guidance and the PMS implementation guide, following key milestones including the go-live of PMS. Closely connected to SPOR, XEVMPD, SIAMED, and various EMA platforms, the IDMP project demands active collaboration between industry and NCAs.
In this session, we cover:
- Key updates to PMS and their impact on industry
- EMA guidance updates and compliance prerequisites
- Use of the Union List of Critical Medicines and the ESMP platform
- PMS as a central source of product data
- Revised IDMP timelines and required industry actions
- MAH obligations and practical implementation challenges
The EMA IDMP project remains active, with increasing complexity. Achieving compliance requires data readiness and process optimisation to meet evolving deadlines and implementation phases.